- Home
- PALI vs ENVB Comparison
PALI vs ENVB Comparison
Compare PALI & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- ENVB
- Stock Information
- Founded
- PALI 1996
- ENVB 1994
- Country
- PALI United States
- ENVB United States
- Employees
- PALI N/A
- ENVB N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- PALI Health Care
- ENVB Health Care
- Exchange
- PALI Nasdaq
- ENVB Nasdaq
- Market Cap
- PALI 3.7M
- ENVB 3.1M
- IPO Year
- PALI N/A
- ENVB N/A
- Fundamental
- Price
- PALI $1.01
- ENVB $1.15
- Analyst Decision
- PALI Strong Buy
- ENVB Strong Buy
- Analyst Count
- PALI 2
- ENVB 1
- Target Price
- PALI $12.00
- ENVB $10.00
- AVG Volume (30 Days)
- PALI 1.1M
- ENVB 179.6K
- Earning Date
- PALI 08-11-2025
- ENVB 08-11-2025
- Dividend Yield
- PALI N/A
- ENVB N/A
- EPS Growth
- PALI N/A
- ENVB N/A
- EPS
- PALI N/A
- ENVB N/A
- Revenue
- PALI N/A
- ENVB N/A
- Revenue This Year
- PALI N/A
- ENVB N/A
- Revenue Next Year
- PALI N/A
- ENVB N/A
- P/E Ratio
- PALI N/A
- ENVB N/A
- Revenue Growth
- PALI N/A
- ENVB N/A
- 52 Week Low
- PALI $0.60
- ENVB $1.01
- 52 Week High
- PALI $4.32
- ENVB $8.95
- Technical
- Relative Strength Index (RSI)
- PALI 56.45
- ENVB 35.60
- Support Level
- PALI $0.95
- ENVB $1.18
- Resistance Level
- PALI $1.40
- ENVB $1.26
- Average True Range (ATR)
- PALI 0.16
- ENVB 0.08
- MACD
- PALI 0.01
- ENVB -0.02
- Stochastic Oscillator
- PALI 42.65
- ENVB 3.10
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.